Serum autotaxin is not a useful biomarker for ovarian cancer

Kazuhiro Nakamura; Koji Igarashi; Ryunosuke Ohkawa; Hiromitsu Yokota; Akiko Masuda; Shunsuke Nakagawa; Tetsu Yano; Hitoshi Ikeda; Junken Aoki; Yutaka Yatomi

doi:10.1007/s11745-012-3691-0

Serum autotaxin is not a useful biomarker for ovarian cancer

Kazuhiro Nakamura, Koji Igarashi, Ryunosuke Ohkawa, Hiromitsu Yokota, Akiko Masuda, Shunsuke Nakagawa, Tetsu Yano, Hitoshi Ikeda, Junken Aoki, Yutaka Yatomi

PHA - Life and Pharmaceutical Science

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Autotaxin (ATX) is a glycoprotein that was first identified in the conditioned medium of human melanoma cells as an autocrine motility factor. It possesses lysophospholipase D activity, producing the bioactive lipid mediator lysophosphatidic acid (LPA) from lysophosphatidylcholine. Enhanced expression of ATX mRNA has been reported in various cancer cells and tissues, and it has been speculated that ATX overexpression in cancer cells may be associated with aberrant LPA production. LPA and ATX have been implicated in cancer progression and metastasis, and ovarian cancer is a representative example. In the present study, we measured the serum ATX antigen levels in patients with ovarian cancer and evaluated the usefulness of this parameter for clinical laboratory testing. The serum ATX antigen levels were not increased in ovarian cancer patients as compared with the levels in healthy subjects, and the serum ATX may not be useful as a biomarker for ovarian cancer.

Original language	English
Pages (from-to)	927-930
Number of pages	4
Journal	Lipids
Volume	47
Issue number	9
DOIs	https://doi.org/10.1007/s11745-012-3691-0
Publication status	Published - 2012 Sept

Keywords

Autotaxin
Clinical laboratory testing
Immunoenzymetric assay
Lysophosphatidic acids
Ovarian cancer
Tumor marker

ASJC Scopus subject areas

Biochemistry
Organic Chemistry
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11745-012-3691-0

Cite this

@article{37b10b2d577d4035b4af5cc948474ea5,

title = "Serum autotaxin is not a useful biomarker for ovarian cancer",

abstract = "Autotaxin (ATX) is a glycoprotein that was first identified in the conditioned medium of human melanoma cells as an autocrine motility factor. It possesses lysophospholipase D activity, producing the bioactive lipid mediator lysophosphatidic acid (LPA) from lysophosphatidylcholine. Enhanced expression of ATX mRNA has been reported in various cancer cells and tissues, and it has been speculated that ATX overexpression in cancer cells may be associated with aberrant LPA production. LPA and ATX have been implicated in cancer progression and metastasis, and ovarian cancer is a representative example. In the present study, we measured the serum ATX antigen levels in patients with ovarian cancer and evaluated the usefulness of this parameter for clinical laboratory testing. The serum ATX antigen levels were not increased in ovarian cancer patients as compared with the levels in healthy subjects, and the serum ATX may not be useful as a biomarker for ovarian cancer.",

keywords = "Autotaxin, Clinical laboratory testing, Immunoenzymetric assay, Lysophosphatidic acids, Ovarian cancer, Tumor marker",

author = "Kazuhiro Nakamura and Koji Igarashi and Ryunosuke Ohkawa and Hiromitsu Yokota and Akiko Masuda and Shunsuke Nakagawa and Tetsu Yano and Hitoshi Ikeda and Junken Aoki and Yutaka Yatomi",

note = "Funding Information: Acknowledgments This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and the Japanese Society of Laboratory Medicine Fund for the Promotion of Scientific Research.",

year = "2012",

month = sep,

doi = "10.1007/s11745-012-3691-0",

language = "English",

volume = "47",

pages = "927--930",

journal = "Lipids",

issn = "0024-4201",

publisher = "Springer Verlag",

number = "9",

}

TY - JOUR

T1 - Serum autotaxin is not a useful biomarker for ovarian cancer

AU - Nakamura, Kazuhiro

AU - Igarashi, Koji

AU - Ohkawa, Ryunosuke

AU - Yokota, Hiromitsu

AU - Masuda, Akiko

AU - Nakagawa, Shunsuke

AU - Yano, Tetsu

AU - Ikeda, Hitoshi

AU - Aoki, Junken

AU - Yatomi, Yutaka

N1 - Funding Information: Acknowledgments This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and the Japanese Society of Laboratory Medicine Fund for the Promotion of Scientific Research.

PY - 2012/9

Y1 - 2012/9

N2 - Autotaxin (ATX) is a glycoprotein that was first identified in the conditioned medium of human melanoma cells as an autocrine motility factor. It possesses lysophospholipase D activity, producing the bioactive lipid mediator lysophosphatidic acid (LPA) from lysophosphatidylcholine. Enhanced expression of ATX mRNA has been reported in various cancer cells and tissues, and it has been speculated that ATX overexpression in cancer cells may be associated with aberrant LPA production. LPA and ATX have been implicated in cancer progression and metastasis, and ovarian cancer is a representative example. In the present study, we measured the serum ATX antigen levels in patients with ovarian cancer and evaluated the usefulness of this parameter for clinical laboratory testing. The serum ATX antigen levels were not increased in ovarian cancer patients as compared with the levels in healthy subjects, and the serum ATX may not be useful as a biomarker for ovarian cancer.

AB - Autotaxin (ATX) is a glycoprotein that was first identified in the conditioned medium of human melanoma cells as an autocrine motility factor. It possesses lysophospholipase D activity, producing the bioactive lipid mediator lysophosphatidic acid (LPA) from lysophosphatidylcholine. Enhanced expression of ATX mRNA has been reported in various cancer cells and tissues, and it has been speculated that ATX overexpression in cancer cells may be associated with aberrant LPA production. LPA and ATX have been implicated in cancer progression and metastasis, and ovarian cancer is a representative example. In the present study, we measured the serum ATX antigen levels in patients with ovarian cancer and evaluated the usefulness of this parameter for clinical laboratory testing. The serum ATX antigen levels were not increased in ovarian cancer patients as compared with the levels in healthy subjects, and the serum ATX may not be useful as a biomarker for ovarian cancer.

KW - Autotaxin

KW - Clinical laboratory testing

KW - Immunoenzymetric assay

KW - Lysophosphatidic acids

KW - Ovarian cancer

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=84866656014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866656014&partnerID=8YFLogxK

U2 - 10.1007/s11745-012-3691-0

DO - 10.1007/s11745-012-3691-0

M3 - Article

C2 - 22700442

AN - SCOPUS:84866656014

SN - 0024-4201

VL - 47

SP - 927

EP - 930

JO - Lipids

JF - Lipids

IS - 9

ER -

Serum autotaxin is not a useful biomarker for ovarian cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this